PubMed=9054892; DOI=10.1016/S0360-3016(96)00449-X
Challeton C., Branea F., Schlumberger M., Gaillard N., de Vathaire F., Badie C., Antonini P., Parmentier C.
Characterization and radiosensitivity at high or low dose rate of four cell lines derived from human thyroid tumors.
Int. J. Radiat. Oncol. Biol. Phys. 37:163-169(1997)
PubMed=17725429; DOI=10.1089/thy.2007.0097
Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V., Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R., Trovisco V., Cirnes L., Alves C., Velho S., Soares P., Sobrinho-Simoes M.
Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.
Thyroid 17:707-715(2007)
PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A., Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)
PubMed=19087340; DOI=10.1186/1471-2407-8-371
Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.
Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples.
BMC Cancer 8:371-371(2008)
PubMed=20143388; DOI=10.1002/ijc.25242
Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A., MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R., Freshney R.I.
Check your cultures! A list of cross-contaminated or misidentified cell lines.
Int. J. Cancer 127:1-8(2010)
PubMed=22087789; DOI=10.1186/1755-8166-4-26
Maric I., Viaggi S., Caria P., Frau D.V., Degan P., Vanni R.
Centrosomal and mitotic abnormalities in cell lines derived from papillary thyroid cancer harboring specific gene alterations.
Mol. Cytogenet. 4:26-26(2011)
PubMed=23162534; DOI=10.3389/fendo.2012.00133
Saiselet M., Floor S., Tarabichi M., Dom G., Hebrant A., van Staveren W.C.G., Maenhaut C.
Thyroid cancer cell lines: an overview.
Front. Endocrinol. 3:133-133(2012)
PubMed=25675381; DOI=10.1210/jc.2014-2764
von Roemeling C.A., Marlow L.A., Pinkerton A.B., Crist A., Miller J., Tun H.W., Smallridge R.C., Copland J.A.
Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.
J. Clin. Endocrinol. Metab. 100:E697-E709(2015)
PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953
Landa I., Pozdeyev N., Korch C., Marlow L.A., Smallridge R.C., Copland J.A., Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)
LncRNA GLTC targets LDHA for succinylation and enzyme activity to promote differentiated thyroid cancer progression and radioiodine resistance ,DOI: https://doi.org/10.21203/rs.3.rs-1949475/v1
LncRNA GLTC targets LDHA for succinylation and enzymatic activity to promote progression and radioiodine resistance in papillary thyroid cancer;Cell Death & Differentiation volume 30, pages1517–1532 (2023)